295 related articles for article (PubMed ID: 12913200)
1. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy.
Loes DJ; Fatemi A; Melhem ER; Gupte N; Bezman L; Moser HW; Raymond GV
Neurology; 2003 Aug; 61(3):369-74. PubMed ID: 12913200
[TBL] [Abstract][Full Text] [Related]
2. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients.
Moser HW; Loes DJ; Melhem ER; Raymond GV; Bezman L; Cox CS; Lu SE
Neuropediatrics; 2000 Oct; 31(5):227-39. PubMed ID: 11204280
[TBL] [Abstract][Full Text] [Related]
3. Adrenoleukodystrophy: magnetic resonance follow-up after Lorenzo's oil therapy.
Duchesne N; Dufour M; Bouchard G; Grondin P; Lemieux B
Can Assoc Radiol J; 1995 Oct; 46(5):386-91. PubMed ID: 7552831
[TBL] [Abstract][Full Text] [Related]
4. Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy.
Eichler FS; Barker PB; Cox C; Edwin D; Ulug AM; Moser HW; Raymond GV
Neurology; 2002 Mar; 58(6):901-7. PubMed ID: 11914405
[TBL] [Abstract][Full Text] [Related]
5. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548
[TBL] [Abstract][Full Text] [Related]
6. [X-linked adrenoleukodystrophy (X-ALD)].
Fenchel M; Korn A; Nägele T; Ernemann U; Horger M
Rofo; 2011 Dec; 183(12):1093-6. PubMed ID: 22220308
[No Abstract] [Full Text] [Related]
7. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil.
Moser HW; Raymond GV; Lu SE; Muenz LR; Moser AB; Xu J; Jones RO; Loes DJ; Melhem ER; Dubey P; Bezman L; Brereton NH; Odone A
Arch Neurol; 2005 Jul; 62(7):1073-80. PubMed ID: 16009761
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for vision loss after hematopoietic cell transplant for X-linked adrenoleukodystrophy.
Gess A; Christiansen SP; Pond D; Peters C
J AAPOS; 2008 Jun; 12(3):273-6. PubMed ID: 18359652
[TBL] [Abstract][Full Text] [Related]
9. Improvement of clinical and MRI findings in a boy with adrenoleukodystrophy by dietary erucic acid therapy.
Maeda K; Suzuki Y; Yajima S; Asano J; Yamaguchi S; Matsumoto N; Borel J; Moser HW; Orii T
Brain Dev; 1992 Nov; 14(6):409-12. PubMed ID: 1492654
[TBL] [Abstract][Full Text] [Related]
10. A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.
Ahmed MA; Kartha RV; Brundage RC; Cloyd J; Basu C; Carlin BP; Jones RO; Moser AB; Fatemi A; Raymond GV
Br J Clin Pharmacol; 2016 Jun; 81(6):1058-66. PubMed ID: 26836218
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics of X-linked adrenoleukodystrophy].
Xiong H; Zhang YH; Qin J; Xiao JX; Shi CY; Zhou SM; Wu XR
Zhonghua Er Ke Za Zhi; 2003 Mar; 41(3):203-7. PubMed ID: 14756960
[TBL] [Abstract][Full Text] [Related]
12. Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy.
Asano J; Suzuki Y; Yajima S; Inoue K; Shimozawa N; Kondo N; Murase M; Orii T
Brain Dev; 1994; 16(6):454-8. PubMed ID: 7694994
[TBL] [Abstract][Full Text] [Related]
13. [A case of adolescent adrenoleukodystrophy with clinical improvement after allogeneic bone marrow transplantation (allo-BMT)].
Tsujii T; Kinoshita M; Tomimoto H; Hitomi T; Okazaki T; Uchiyama T; Shibasaki H
Rinsho Shinkeigaku; 2004 Oct; 44(10):667-72. PubMed ID: 15568481
[TBL] [Abstract][Full Text] [Related]
14. MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy.
Fatemi A; Barker PB; Uluğ AM; Nagae-Poetscher LM; Beauchamp NJ; Moser AB; Raymond GV; Moser HW; Naidu S
Neurology; 2003 Apr; 60(8):1301-7. PubMed ID: 12707433
[TBL] [Abstract][Full Text] [Related]
15. Progress in X-linked adrenoleukodystrophy.
Moser H; Dubey P; Fatemi A
Curr Opin Neurol; 2004 Jun; 17(3):263-9. PubMed ID: 15167059
[TBL] [Abstract][Full Text] [Related]
16. Adrenoleukodystrophy: a link between adrenal insufficiency and school performance.
Bakos JT; Goen P; Ogden A; Brown FR; Karaviti LP
J Clin Endocrinol Metab; 1995 Oct; 80(10):2869-72. PubMed ID: 7559867
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychological testing may predict early progression of asymptomatic adrenoleukodystrophy.
Riva D; Bova SM; Bruzzone MG
Neurology; 2000 Apr; 54(8):1651-5. PubMed ID: 10762508
[TBL] [Abstract][Full Text] [Related]
18. Adrenoleukodystrophy: new approaches to a neurodegenerative disease.
Moser HW; Raymond GV; Dubey P
JAMA; 2005 Dec; 294(24):3131-4. PubMed ID: 16380594
[TBL] [Abstract][Full Text] [Related]
19. [Primary adrenal insufficiency as the form of onset of adrenoleukodystrophy in a 4-year-old boy].
Tornero Patricio S; de la Vega JA; Nehme Alvarez D; Gentil González FJ; Lluch Fernández MD; González Hachero J
Endocrinol Nutr; 2009 Jan; 56(1):40-2. PubMed ID: 19627707
[TBL] [Abstract][Full Text] [Related]
20. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy.
Aubourg P; Adamsbaum C; Lavallard-Rousseau MC; Rocchiccioli F; Cartier N; Jambaqué I; Jakobezak C; Lemaitre A; Boureau F; Wolf C
N Engl J Med; 1993 Sep; 329(11):745-52. PubMed ID: 8350883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
